Seagen hailed the outcome of the lawsuit, saying it will now seek royalties on all future US sales of Enhertu through the remaining lifespan of the patent, which expires in November 2024.

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing ...

AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

The inclusion of Enhertu comes after AstraZeneca said earlier ... 2 pharmaceuticals market, with sales from the country contributing 13% of its overall revenue. A spokesperson for Daiichi Sankyo ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

We are extremely disappointed that talks to reach a price agreement that would have made advanced breast cancer drug Enhertu available to around 1000 women in England and Wales have not been ...

Alteogen Inc. scored another deal for its human recombinant enzyme, ALT-B4, on Nov. 8, reeling in Daiichi Sankyo Co. Ltd. in a potential $300 million deal including $20 million up front and up to $280 ...

AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the ...

The National Institute for Health and Care Excellence (Nice) said it is “extremely disappointed” it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.